MRNS - Marinus Pharmaceuticals Inc Stock Price, Fair Value and News

$0.55

Market Closed

MRNS Stock Valuation Analysis

Valuation

Max Portfolio %

MRNS Price Action

MRNS RSI Chart

MRNS Stock Valuation Analysis

Valuation

Max Portfolio %

MRNS Valuation

MRNS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MRNS Fundamentals

MRNS Revenue

MRNS Earnings

MRNS Profitability

MRNS Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	28.3M	30.3M	31.5M	0
2023	21.7M	26.0M	31.0M	31.0M
2022	27.7M	27.6M	19.8M	25.5M
2021	3.6M	5.4M	15.4M	15.3M
2020	0	0	276.5K	1.8M
2016	72.0K	91.0K	112.0K	127.5K
2015	23.5K	37.5K	48.5K	64.0K
2014	38.6K	30.3K	21.9K	13.5K
2013	0	0	0	47.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

CEO	Dr. Scott N. Braunstein M.D.
WEBSITE	https://marinuspharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	151